Cogent Biosciences Inc
For the period ended Dec 31, 2024. Filed Feb 25, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 25, 2025
COGT$33.54+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share and per share amounts)
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $98,165 | $53,229 |
| Short-term marketable securities | 188,912 | 212,481 |
| Prepaid expenses and other current assets | 9,395 | 5,061 |
| Total current assets | 296,472 | 270,771 |
| Long-term marketable securities | — | 7,460 |
| Operating lease, right-of-use assets | 20,097 | 21,998 |
| Property and equipment, net | 6,467 | 8,344 |
| Other assets | 4,862 | 4,864 |
| Total assets | $327,898 | $313,437 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $12,013 | $10,655 |
| Accrued expenses and other current liabilities | 42,132 | 26,127 |
| Operating lease liabilities | 1,565 | 1,386 |
| Total current liabilities | 55,710 | 38,168 |
| Operating lease liabilities, net of current portion | 15,902 | 17,467 |
| Total liabilities | 71,612 | 55,635 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value; 8,979,420 shares authorized; no shares issued or outstanding | — | — |
| Series A non-voting convertible preferred stock, $0.001 par value; 1,000,000 shares authorized; 70,465 and 74,465 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 56,515 | 60,035 |
| Series B non-voting convertible preferred stock, $0.001 par value; 20,580 shares authorized; 6,868 and no shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 54,085 | — |
| Common stock, $0.001 par value; 300,000,000 shares authorized; 110,461,729 shares and 86,124,249 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively | 110 | 86 |
| Additional paid-in capital | 1,004,612 | 801,059 |
| Accumulated other comprehensive income | 447 | 246 |
| Accumulated deficit | (859,483) | (603,624) |
| Total stockholders’ equity | 256,286 | 257,802 |
| Total liabilities and stockholders’ equity | $327,898 | $313,437 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.